310.38
Praxis Precision Medicines Inc Borsa (PRAX) Ultime notizie
A Look At Praxis Precision Medicines (PRAX) Valuation After FDA Priority Review For Relutrigine - Yahoo Finance
Praxis Precision Medicines (PRAX) reports $926M 2025 cash balance, extended runway - MSN
Aberdeen Group plc Takes $39.79 Million Position in Praxis Precision Medicines, Inc. $PRAX - MarketBeat
PRAX Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
SG Americas Securities LLC Cuts Position in Praxis Precision Medicines, Inc. $PRAX - MarketBeat
(PRAX) Risk Channels and Responsive Allocation - Stock Traders Daily
Praxis Precision Medicines, Inc. (PRAX) stock price, news, quote and history - Yahoo Finance UK
Praxis Precision Medicines announces inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Praxis Precision Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView
Praxis Precision Medicines, Inc. (PRAX) Stock Price, News, Quote & History - Yahoo! Finance Canada
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - ChartMill
PRAX SEC FilingsPraxis Precision Medicines, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Guggenheim Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $800 - Moomoo
Praxis Precision Medicines (NASDAQ:PRAX) Trading Up 13.4%Time to Buy? - MarketBeat
Jefferies Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Raises Target Price to $525 - Moomoo
Why Did Praxis Precision Medicines Stock Surge 69% In Pre-Market Today? - MSN
PRAX Stock Price, Quote & Chart | PRAXIS PRECISION MEDICINES I (NASDAQ:PRAX) - ChartMill
FDA Prioritizes Review of Praxis Precision's (PRAX) Drug Applica - GuruFocus
Praxis Precision Medicines Gets FDA Priority Review for Relutrigine - marketscreener.com
Praxis Precision Medicines Announces FDA Acceptance and Priority Review of New Drug Application for Relutrigine in Patients with SCN2A and SCN8A DEEs - Bitget
FDA fast-tracks Praxis drug for rare childhood epilepsy disorders - Stock Titan
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Vanguard subsidiaries disaggregate holdings; Praxis (PRAX) shows 0 shares reported - Stock Titan
Praxis Precision Medicines (NASDAQ:PRAX) Raised to Strong-Buy at Truist Financial - MarketBeat
(PRAX) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Biotech Stock Up 685% Draws $80.5 Million Investment Amid Dual FDA Filings - AOL.com
This Biotech Stock Up 700% Is Still a Top Holding Despite a $9.3 Million Sale Last Quarter - AOL.com
Aug Swings: Is Praxis Precision Medicines Inc forming bullish engulfing patterns2026 Reactions & Reliable Momentum Entry Alerts - baoquankhu1.vn
Praxis Stock Has Surged 700% in a Year, and This Fund Is Betting $266 Million on Its Pipeline - AOL.com
5AM Venture Divests Entire Praxis Precision Medicines Position | February 2026 FilingNews and Statistics - IndexBox
Biotech Stock Still Up 700% Despite 30% Drop This Year as One Fund Discloses $9 Million Exit - AOL.com
Will Extended Cash Runway And Dual FDA Filings Shift Praxis Precision Medicines' (PRAX) Narrative Toward Commercialization? - Yahoo Finance
Praxis Precision Medicines (PRAX) Reports $926M 2025 Cash Balance, Extended Runway - Insider Monkey
PRAX PE Ratio & Valuation, Is PRAX Overvalued - Intellectia AI
Praxis Stock Surges 320% as One Biotech Investor's Buy Pushes Stake to Nearly $600 Million - AOL.com
Algert Global LLC Increases Stock Position in Praxis Precision Medicines, Inc. $PRAX - MarketBeat
Cormorant Sells $9.31M in Praxis Shares, Holding Remains Top Position | 2026 UpdateNews and Statistics - IndexBox
This biotech stock, which has surged by 700%, remains one of the leading holdings even after a $9.3 million sale in the previous quarter. - Bitget
This Biotech Stock Up 700% Is Still a Top Holding Despite a $9.3 Million Sale Last Quarter - The Motley Fool
HighVista Strategies LLC Has $5.04 Million Stock Position in Praxis Precision Medicines, Inc. $PRAX - MarketBeat
Praxis Precision Medicines (PRAX) Is Down 5.4% After Major Institutional Buying and FDA FilingsHas The Bull Case Changed? - simplywall.st
Is Praxis Precision Medicines (PRAX) Still Attractive After Its Big Share Price Run? - Yahoo Finance
Praxis FDA Filings Shift Focus From Pipeline Promise To Potential Revenue - Yahoo Finance
PRAX Technical Analysis & Stock Price Forecast - Intellectia AI
Praxis Precision Medicines, Inc. $PRAX Shares Sold by B Group Inc. - MarketBeat
Investor Buys Up $81 Million in Praxis Stock as Shares Soar Over 300% in One Year - AOL.com
A Look At Praxis Precision Medicines (PRAX) Valuation After New Driehaus Investment And Recent FDA Filings - simplywall.st
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):